Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PRO1107 in advanced solid tumors
CTR20242075Phase 2Terminated
- Sponsor
- ProfoundBio
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pro1107 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), endometrial cancer (EC), triple-negative breast cancer (TNBC), sponsored by ProfoundBio. Started Sep 2024; status: terminated.
02
Drugs
pro1107
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20242075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242075.